Seeking Alpha

Amarin (AMRN +1%) gains after saying it's submitted a Supplemental New Drug Application with the...

Amarin (AMRN +1%) gains after saying it's submitted a Supplemental New Drug Application with the FDA seeking approval for the marketing and sale of Vascepa capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides with mixed dyslipidemia. The drug is already approved to treat hypertriglyceridemia, and if cleared for the new indication, it will be the only approved prescription omega 3 therapy for cardiovascular health management in this patient population.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)